

# Gunjan L Shah

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7170098/publications.pdf>

Version: 2024-02-01

102  
papers

2,987  
citations

172207

29  
h-index

189595

50  
g-index

103  
all docs

103  
docs citations

103  
times ranked

4241  
citing authors

| #  | ARTICLE  | IF   | CITATIONS |
|----|--|------|-----------|
| 1  | Microbiota as Predictor of Mortality in Allogeneic Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2020, 382, 822-834.  | 13.9 | 435       |
| 2  | Clinical characteristics and outcomes of COVID-19 in haematopoietic stem-cell transplantation recipients: an observational cohort study. <i>Lancet Haematology</i> , 2021, 8, e185-e193.                                     | 2.2  | 271       |
| 3  | Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies. <i>Blood Advances</i> , 2020, 4, 3776-3787.  | 2.5  | 162       |
| 4  | Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma. <i>Blood Cancer Journal</i> , 2020, 10, 79.   | 2.8  | 137       |
| 5  | Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management. <i>Blood Advances</i> , 2020, 4, 676-686.  | 2.5  | 101       |
| 6  | Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. <i>Journal of Clinical Investigation</i> , 2020, 130, 6656-6667.   | 3.9  | 101       |
| 7  | DLBCL patients treated with CD19 CAR T cells experience a high burden of organ toxicities but low nonrelapse mortality. <i>Blood Advances</i> , 2020, 4, 3024-3033.  | 2.5  | 75        |
| 8  | Clinical Responses and Pharmacokinetics of MCARH171, a Human-Derived Bcma Targeted CAR T Cell Therapy in Relapsed/Refractory Multiple Myeloma: Final Results of a Phase I Clinical Trial. <i>Blood</i> , 2018, 132, 959-959. | 0.6  | 71        |
| 9  | Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies. <i>Cancer Cell</i> , 2022, 40, 590-591.   | 7.7  | 70        |
| 10 | Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies. <i>Blood Advances</i> , 2020, 4, 4669-4678.   | 2.5  | 64        |
| 11 | Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma. <i>JAMA Oncology</i> , 2021, 7, 862.                    | 3.4  | 63        |
| 12 | Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies. <i>Blood Cancer Discovery</i> , 2021, 2, 568-576.  | 2.6  | 62        |
| 13 | Impact of TP53 Genomic Alterations in Large B-Cell Lymphoma Treated With CD19-Chimeric Antigen Receptor T-Cell Therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 369-381.   | 0.8  | 60        |
| 14 | Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cells. <i>Blood Advances</i> , 2021, 5, 3397-3406.  | 2.5  | 59        |
| 15 | Gain of chromosome 1q portends worse prognosis in multiple myeloma despite novel agent-based induction regimens and autologous transplantation. <i>Leukemia and Lymphoma</i> , 2017, 58, 1823-1831.                          | 0.6  | 57        |
| 16 | Patient-Reported Outcomes with Chimeric Antigen Receptor T Cell Therapy: Challenges and Opportunities. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e155-e162.   | 2.0  | 56        |
| 17 | Early experience using salvage radiotherapy for relapsed/refractory non-Hodgkin lymphomas after CD19 chimeric antigen receptor (CAR) T cell therapy. <i>British Journal of Haematology</i> , 2020, 190, 45-51.               | 1.2  | 51        |
| 18 | Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. <i>Lancet Haematology</i> , 2021, 8, e422-e432.                   | 2.2  | 50        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma. <i>Cancer</i> , 2020, 126, 5077-5087.   | 2.0 | 47        |
| 20 | Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. <i>Leukemia</i> , 2021, 35, 2672-2683.  | 3.3 | 45        |
| 21 | Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy. <i>Blood Cancer Discovery</i> , 2021, 2, 577-585.  | 2.6 | 44        |
| 22 | Accelerated single cell seeding in relapsed multiple myeloma. <i>Nature Communications</i> , 2020, 11, 3617.   | 5.8 | 41        |
| 23 | Transplant strategies in relapsed/refractory Hodgkin lymphoma. <i>Blood</i> , 2018, 131, 1689-1697.  | 0.6 | 36        |
| 24 | What Intensivists Need to Know About Hemophagocytic Syndrome. <i>Journal of Intensive Care Medicine</i> , 2012, 27, 58-64.   | 1.3 | 35        |
| 25 | Revaccination after Autologous Hematopoietic Stem Cell Transplantation Is Safe and Effective in Patients with Multiple Myeloma Receiving Lenalidomide Maintenance. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 871-876.                             | 2.0 | 35        |
| 26 | Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy Provides Unprecedented MRD Negativity Rates in Newly Diagnosed Multiple Myeloma: A Clinical and Correlative Phase 2 Study. <i>Blood</i> , 2019, 134, 862-862.             | 0.6 | 34        |
| 27 | Value of innovation in hematologic malignancies: a systematic review of published cost-effectiveness analyses. <i>Blood</i> , 2015, 125, 1866-1869.  | 0.6 | 32        |
| 28 | Robust Vaccine Responses in Adult and Pediatric Cord Blood Transplantation Recipients Treated for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2160-2166.  | 2.0 | 31        |
| 29 | Cost-Effectiveness of Autologous Hematopoietic Stem Cell Transplantation for Elderly Patients with Multiple Myeloma using the Surveillance, Epidemiology, and End Results Medicare Database. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1823-1829. | 2.0 | 30        |
| 30 | The Real World Effectiveness of Hematopoietic Transplant Among Elderly Individuals With Multiple Myeloma. <i>Journal of the National Cancer Institute</i> , 2015, 107, .   | 3.0 | 29        |
| 31 | High progression-free survival after intermediate intensity double unit cord blood transplantation in adults. <i>Blood Advances</i> , 2020, 4, 6064-6076.  | 2.5 | 29        |
| 32 | Risk factors predicting outcomes for primary refractory hodgkin lymphoma patients treated with salvage chemotherapy and autologous stem cell transplantation. <i>British Journal of Haematology</i> , 2016, 175, 440-447.  | 1.2 | 27        |
| 33 | Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma. <i>Leukemia</i> , 2019, 33, 2540-2544.   | 3.3 | 26        |
| 34 | The International Prognostic Index Is Associated with Outcomes in Diffuse Large B Cell Lymphoma after Chimeric Antigen Receptor T Cell Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 233-240.   | 0.6 | 24        |
| 35 | A Phase II Study of Prophylactic Anakinra to Prevent CRS and Neurotoxicity in Patients Receiving CD19 CAR T Cell Therapy for Relapsed or Refractory Lymphoma. <i>Blood</i> , 2021, 138, 96-96.   | 0.6 | 24        |
| 36 | Toxicities of high-dose chemotherapy and autologous hematopoietic cell transplantation in older patients with lymphoma. <i>Blood Advances</i> , 2021, 5, 2608-2618.  | 2.5 | 22        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 37 | Medicare Patients Receiving Chimeric Antigen Receptor T-Cell Therapy for Non-Hodgkin Lymphoma: A First Real-World Look at Patient Characteristics, Healthcare Utilization and Costs. <i>Blood</i> , 2019, 134, 793-793.  | 0.6 | 22        |
| 38 | Pretransplant comprehensive geriatric assessment in hematopoietic cell transplantation: a single center experience. <i>Bone Marrow Transplantation</i> , 2018, 53, 1184-1187.  | 1.3 | 21        |
| 39 | Outcome of Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis Associated With Deletion of 17p. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e493-e499.   | 0.2 | 20        |
| 40 | Bortezomib Subcutaneous Injection in Combination Regimens for Myeloma or Systemic Light-Chain Amyloidosis: A Retrospective Chart Review of Response Rates and Toxicity in Newly Diagnosed Patients. <i>Clinical Therapeutics</i> , 2013, 35, 1614-1620.                        | 1.1 | 18        |
| 41 | Value-Based Care in Hematopoietic Cell Transplantation and Cellular Therapy: Challenges and Opportunities. <i>Current Hematologic Malignancy Reports</i> , 2018, 13, 125-134.  | 1.2 | 18        |
| 42 | Phase I Study of Selinexor, Ixazomib, and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2020, 20, 198-200.   | 0.2 | 17        |
| 43 | The Simplified Comorbidity Index: a new tool for prediction of nonrelapse mortality in allo-HCT. <i>Blood Advances</i> , 2022, 6, 1525-1535.   | 2.5 | 17        |
| 44 | Relapse after Allogeneic Stem Cell Transplantation of Acute Myelogenous Leukemia and Myelodysplastic Syndrome and the Importance of Second Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 771.e1-771.e10.   | 0.6 | 17        |
| 45 | Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity. <i>Leukemia and Lymphoma</i> , 2018, 59, 1981-1985.   | 0.6 | 16        |
| 46 | Impact of Toxicity on Survival for Older Adult Patients after CD34+ Selected Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 142-149.   | 2.0 | 16        |
| 47 | Role of CD19 Chimeric Antigen Receptor T Cells in Second-Line Large B Cell Lymphoma: Lessons from Phase 3 Trials. An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 546-559. | 0.6 | 16        |
| 48 | Unlocking the Complex Flavors of Dysgeusia after Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 425-432.   | 2.0 | 15        |
| 49 | Standard Antithymocyte Globulin Dosing Results in Poorer Outcomes in Overexposed Patients after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1526-1535.                                | 2.0 | 15        |
| 50 | Significant Nationwide Variability in the Costs and Hospital Mortality Rates of Autologous Stem Cell Transplantation for Multiple Myeloma: An Analysis of the Nationwide Inpatient Sample Database. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 41-46.      | 2.0 | 15        |
| 51 | Early Fluid Overload Is Associated with an Increased Risk of Nonrelapse Mortality after Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2517-2522.   | 2.0 | 13        |
| 52 | Antithymocyte globulin exposure in CD34+ T-cell-depleted allogeneic hematopoietic cell transplantation. <i>Blood Advances</i> , 2022, 6, 1054-1063.  | 2.5 | 12        |
| 53 | Mitomycin-C-Induced TTP/HUS Treated Successfully with Rituximab: Case Report and Review of the Literature. <i>Case Reports in Hematology</i> , 2013, 2013, 1-3.  | 0.3 | 11        |
| 54 | The Impact of Toxicities on First-Year Outcomes after Ex Vivo CD34+ Selected Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2004-2011.                                  | 2.0 | 11        |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 55 | Effects of Late Toxicities on Outcomes in Long-Term Survivors of Ex-Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 133-141.  | 2.0 | 11        |
| 56 | Cellular Therapy During COVID-19: Lessons Learned and Preparing for Subsequent Waves. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 438.e1-438.e6.  | 0.6 | 11        |
| 57 | Extended-duration letermovir prophylaxis for cytomegalovirus infection after cord blood transplantation in adults. <i>Blood Advances</i> , 2022, 6, 6291-6300.  | 2.5 | 11        |
| 58 | Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m <sup>2</sup> ) in combination with lenalidomide and dexamethasone. <i>American Journal of Hematology</i> , 2021, 96, E193-E196. | 2.0 | 10        |
| 59 | Incidence and Evaluation of Incidental Abnormal Bone Marrow Signal on Magnetic Resonance Imaging. <i>Scientific World Journal</i> , The, 2014, 2014, 1-6.   | 0.8 | 9         |
| 60 | Measurement of the DNA alkylating agents busulfan and melphalan in human plasma by mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2019, 1125, 121711.   | 1.2 | 9         |
| 61 | Loss of Microbiota Diversity after Autologous Stem Cell Transplant Is Comparable to Injury in Allogeneic Stem Cell Transplant. <i>Blood</i> , 2018, 132, 608-608.   | 0.6 | 9         |
| 62 | Presalvage International Staging System Stage and Other Important Outcome Associations in CD34+-Selected Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 58-65.                                       | 2.0 | 8         |
| 63 | Stem Cell Mobilization and Autograft Minimal Residual Disease Negativity with Novel Induction Regimens in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 1394-1401.   | 2.0 | 8         |
| 64 | Immune Cytopenias after Ex Vivo CD34+-Selected Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1136-1141.   | 2.0 | 7         |
| 65 | Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality. <i>Leukemia and Lymphoma</i> , 2021, 62, 1940-1948.  | 0.6 | 7         |
| 66 | Belantamab Mafodotin in Patients with Relapsed/Refractory Multiple Myeloma, a Real-World Experience. <i>Blood</i> , 2021, 138, 1644-1644.   | 0.6 | 7         |
| 67 | Subcutaneous Bortezomib in Combination Regimens in Newly Diagnosed Patients with Myeloma or Systemic AL Amyloidosis: High Response Rates and Minimal Toxicity.. <i>Blood</i> , 2012, 120, 2968-2968.  | 0.6 | 5         |
| 68 | Hematopoietic Cell Transplantation is Feasible in Patients with Prior COVID-19 Infection. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 55.e1-55.e5.  | 0.6 | 5         |
| 69 | Thirty Day Resource Utilization after Chimeric Antigen Receptor (CAR) T Cell Infusion for Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, S38-S39.   | 2.0 | 4         |
| 70 | Geriatric syndromes in 2-year, progression-free survivors among older recipients of allogeneic hematopoietic cell transplantation. <i>Bone Marrow Transplantation</i> , 2021, 56, 289-292.  | 1.3 | 4         |
| 71 | African American patients with smoldering multiple myeloma may have a lower risk of progression compared to White patients.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8045-8045.   | 0.8 | 4         |
| 72 | Cost Implications of Comorbidity for Autologous Stem Cell Transplantation in Elderly Patients with Multiple Myeloma Using SEER-Medicare. <i>Bone Marrow Research</i> , 2016, 2016, 1-6.   | 1.7 | 3         |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 73 | Infectious Complications in Aggressive B Cell Non-Hodgkin Lymphoma after CD-19 Chimeric Antigen Receptor T Cell Therapy. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S326.  | 2.0 | 3         |
| 74 | Role of Positron Emission Tomography in Diffuse Large B-cell Lymphoma. <i>Hematology/Oncology Clinics of North America</i> , 2016, 30, 1215-1228.  | 0.9 | 2         |
| 75 | Jettison-MS of Nucleic Acid Species. <i>Journal of the American Society for Mass Spectrometry</i> , 2020, 31, 1641-1646.   | 1.2 | 2         |
| 76 | Homebound Autologous Hematopoietic Cell Transplantation for Plasma Cell Disorders in an Urban Setting Is Safe for Patients and Preferred By Patients and Caregivers. <i>Blood</i> , 2018, 132, 2258-2258.  | 0.6 | 2         |
| 77 | Association of Patient Activity Bioprofiles with Hrql and Clinical Responses: A Prospective Novel Trial Using Mobile Wearables in Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2020, 136, 26-28.  | 0.6 | 2         |
| 78 | Capture Rate of V(D)J Sequencing for Minimal Residual Disease Detection in Multiple Myeloma. <i>Clinical Cancer Research</i> , 2022, 28, 2160-2166.  | 3.2 | 2         |
| 79 | Early Toxicities Associated with Radiation Based Conditioning for Relapsed/Refractory Hodgkin Lymphoma Patients Undergoing High Dose Therapy and Autologous Stem Cell Transplantation (HDT-ASCT). <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, S142-S143.  | 2.0 | 1         |
| 80 | Disease Progression is Main Barrier to Allogeneic Hematopoietic Stem Cell Transplantation (HCT) in Patients with Newly Diagnosed and Relapsed Acute Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, S323-S324.  | 2.0 | 1         |
| 81 | Prognostic Factors for Postrelapse Survival after ex Vivo CD34+-Selected (T Cell-Depleted) Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2040-2046.  | 2.0 | 1         |
| 82 | Characteristics and Impact of Post-Transplant Interdisciplinary Palliative Care Consultation in Older Allogeneic Hematopoietic Cell Transplant Recipients. <i>Journal of Palliative Medicine</i> , 2020, 23, 1653-1657.  | 0.6 | 1         |
| 83 | Survival for Relapsed/Refractory Hodgkin Lymphoma Patients with Recurrent or Persistent Disease Following Autologous Hematopoietic Stem Cell Transplantation Treated in the Modern Era. <i>Blood</i> , 2018, 132, 2148-2148.   | 0.6 | 1         |
| 84 | Abnormal bone marrow signal on MRI heralding oncologic diagnoses: A single institution review.. <i>Journal of Clinical Oncology</i> , 2013, 31, 1580-1580.   | 0.8 | 1         |
| 85 | Cost-Implications Of Comorbidity For Autologous Hematopoietic Stem Cell Transplantation (Auto) Tj ETQq1 1 0.784314 rgBT /Overlo<br>122, 1746-1746.   | 0.6 | 1         |
| 86 | Effect of Obesity on the Efficacy and Toxicities in Patients Undergoing Autologous Hematopoietic Stem Cell Transplant (AHCT) for Lymphoma. <i>Blood</i> , 2018, 132, 4617-4617.  | 0.6 | 1         |
| 87 | Chemotherapy-Related Mutational Signatures Reveal the Origins of Therapy-Related Myeloid Neoplasms. <i>Blood</i> , 2021, 138, 3271-3271.   | 0.6 | 1         |
| 88 | Timing and Immune Status after Cellular Therapies Predict Response to COVID-19 Vaccines. <i>Blood</i> , 2021, 138, 3891-3891.  | 0.6 | 1         |
| 89 | Clinical Impact of Bridging Therapy Prior to Commercial Chimeric Antigen Receptor (CAR) T-Cell Therapies for Relapsed/Refractory Lymphomas. <i>Blood</i> , 2020, 136, 1-2.   | 0.6 | 1         |
| 90 | VRd Versus KRd Safety Profiles in Newly Diagnosed Multiple Myeloma Patients Using Real-World Evidence Data from a Single Institution: VRd Has High Rates of Chronic Neuropathy, and KRd Has Low Rates of Cardiopulmonary or Renal Toxicities When Using Optimized IV Fluid Management Coupled with Baseline Cardiac Workup. <i>Blood</i> , 2020, 136, 37-38. | 0.6 | 1         |

| #   | ARTICLE   | IF  | CITATIONS |
|-----|---|-----|-----------|
| 91  | Weekly Carfilzomib, Lenalidomide, Dexamethasone and Daratumumab (wKRd-D) Combination Therapy in Newly Diagnosed Multiple Myeloma: Final Results from a Clinical and Correlative Phase 2 Study. Blood, 2020, 136, 7-7.   | 0.6 | 1         |
| 92  | Evaluating serum-free light chain ratio as a biomarker for multiple myeloma.. Journal of Clinical Oncology, 2022, 40, 8047-8047.  | 0.8 | 1         |
| 93  | Absolute Lymphocyte Count As Predictor of Survival Following Hematopoietic Stem Cell Transplants. Blood, 2011, 118, 4538-4538.  | 0.6 | 0         |
| 94  | Plerixafor and G-CSF For Autologous Stem Cell Mobilization In AL Amyloidosis: A Single Center Experience. Blood, 2013, 122, 4516-4516.  | 0.6 | 0         |
| 95  | Long-Term Sustained Minimal Residual Disease (MRD) Negativity in Patients with Multiple Myeloma Treated with Continuous Lenalidomide Maintenance Therapy: A Clinical and Correlative Phase 2 Study. Blood, 2020, 136, 18-19.  | 0.6 | 0         |
| 96  | Cost and Healthcare Utilization in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Real-World Analysis of Medicare Beneficiaries Receiving Chimeric Antigen Receptor T-Cell Vs. Autologous and Allogeneic Hematopoietic Cell Transplants. Blood, 2020, 136, 4-4. | 0.6 | 0         |
| 97  | A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study). Blood, 2020, 136, 8-10.  | 0.6 | 0         |
| 98  | Rabbit Anti-Thymocyte Globulin Exposure (rATG) in CD34+ Selected Hematopoietic Cell Transplantation and Its Impact on Immune Reconstitution and Outcomes in Children and Adults. Blood, 2020, 136, 30-31.   | 0.6 | 0         |
| 99  | Evaluation of Melphalan Exposure in Lymphoma Patients Undergoing BEAM and Autologous Hematopoietic Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 485.e1-485.e6.   | 0.6 | 0         |
| 100 | Minimal Residual Disease Negativity in Multiple Myeloma: One Good Season Is Not Enough. , 2022, 19, .   |     | 0         |
| 101 | Patient preferences for second-line treatment options in diffuse large B-cell lymphoma: A discrete choice experiment.. Journal of Clinical Oncology, 2022, 40, e19558-e19558.   | 0.8 | 0         |
| 102 | Clinical efficacy of daratumumab (DARA)-based second line therapy after DARA-containing and DARA-free induction therapies in multiple myeloma: A single center experience.. Journal of Clinical Oncology, 2022, 40, e20005-e20005.                                    | 0.8 | 0         |